Literature DB >> 24676426

Evaluation of the 7th edition of the TNM classification for lung cancer at a single institution.

Jia Wang1, Nan Wu, Qingfeng Zheng, Yuan Feng, Shi Yan, Chao Lv, Shaolei Li, Yuzhao Wang, Yue Yang.   

Abstract

PURPOSE: To assess the utilities and drawbacks of the 7th edition of the TNM classification for lung cancer.
METHODS: Subjects included 1,469 patients who underwent pulmonary resection for primary non-small cell lung cancer. Survival characteristics were compared using the 6th and 7th editions of the staging system.
RESULTS: According to the 6th and 7th editions, respectively, the 5-year survival rates based on stages were as follows: pStage IA (81.0, 81.0 %), pStage IB (70.6, 72.0 %), pStage IIA (61.3, 59.7 %), pStage IIB (56.6, 47.2 %), pStage IIIA (43.4, 37.6 %), pStage IIIB (8.9, 14.9 %), and pStage IV (14.0, 8.0 %). According to the 6th edition, there was no significant difference between pStages IB and IIA (P = 0.268), or between pStages IIA and IIB (P = 0.622), or between pStages IIIB and IV (P = 0.737). According to the 7th edition, there were significant differences between each adjacent stage group, except between pStages IIIB and IV (P = 0.424). According to the 7th edition staging system, 5-year survival rates by T classification were as follows: pT1a, 81.6 %; pT1b, 75.9 %; pT2a, 60.1 %; pT2b, 44.7 %; pT3, 24.4 %; and pT4, 13.2 %; with significant differences between each adjacent pT classification. The 5-year survival rates by M classification were as follows: M0, 57.2 %, M1a, 9.1 %, M1b, 0 %, with a significant difference between M0 and M1a, but there was no significant difference between M1a and M1b.
CONCLUSION: The UICC 7th edition staging system is considered valid for non-small cell lung cancer patients and appears to be superior in defining different prognostic groups than the 6th edition.

Entities:  

Mesh:

Year:  2014        PMID: 24676426     DOI: 10.1007/s00432-014-1636-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  22 in total

1.  Comparison of the 6th and 7th editions of the American Joint Committee on Cancer tumor-node-metastasis staging system in patients with resected esophageal carcinoma.

Authors:  Po-Kuei Hsu; Yu-Chung Wu; Teh-Ying Chou; Chien-Sheng Huang; Wen-Hu Hsu
Journal:  Ann Thorac Surg       Date:  2010-04       Impact factor: 4.330

2.  Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor.

Authors:  D Manac'h; M Riquet; J Medioni; F Le Pimpec-Barthes; A Dujon; C Danel
Journal:  Ann Thorac Surg       Date:  2001-04       Impact factor: 4.330

3.  Survival after pathological stage IA nonsmall cell lung cancer: tumor size matters.

Authors:  Ozcan Birim; A Pieter Kappetein; Johanna J M Takkenberg; Rob J van Klaveren; Ad J J C Bogers
Journal:  Ann Thorac Surg       Date:  2005-04       Impact factor: 4.330

4.  Revisit of 1997 TNM staging system--survival analysis of 1112 lung cancer patients in Taiwan.

Authors:  Reury-Perng Perng; Chih-Yi Chen; Gee-Chen Chang; Te-Chun Hsia; Nan-Yung Hsu; Ying-Huang Tsai; Chun-Ming Tsai; Chih-Hsin Yang; Yuh-Min Chen; Chong-Jen Yu; Jen-Jyh Lee; Han-Shui Hsu; Chih-Teng Yu; Eing-Long Kao; Chao-Hua Chiu
Journal:  Jpn J Clin Oncol       Date:  2006-12-01       Impact factor: 3.019

5.  Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients.

Authors:  Joachim Pfannschmidt; Thomas Muley; Heinrich Bülzebruck; Hans Hoffmann; Hendrik Dienemann
Journal:  Lung Cancer       Date:  2006-11-22       Impact factor: 5.705

6.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

7.  Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study.

Authors:  Tomoyuki Goya; Hisao Asamura; Hirokuni Yoshimura; Harubumi Kato; Kaoru Shimokata; Ryosuke Tsuchiya; Yasunori Sohara; Toshimichi Miya; Etsuo Miyaoka
Journal:  Lung Cancer       Date:  2005-08-02       Impact factor: 5.705

8.  Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non-small cell lung cancers.

Authors:  Takayuki Fukui; Shoichi Mori; Shunzo Hatooka; Masayuki Shinoda; Tetsuya Mitsudomi
Journal:  J Thorac Cardiovasc Surg       Date:  2008-08-15       Impact factor: 5.209

9.  Subdivision of the T1 size descriptor for stage I non-small cell lung cancer has prognostic value: a single institution experience.

Authors:  Chao Ye; Justin R Masterman; Mark S Huberman; Sidhu P Gangadharan; Danielle C McDonald; Michael S Kent; Malcolm M DeCamp
Journal:  Chest       Date:  2009-06-12       Impact factor: 9.410

10.  The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer.

Authors:  Ramón Rami-Porta; David Ball; John Crowley; Dorothy J Giroux; James Jett; William D Travis; Masahiro Tsuboi; Eric Vallières; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2007-07       Impact factor: 15.609

View more
  8 in total

1.  Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung cancer patients.

Authors:  Nicholas T Woods; Alvaro N Monteiro; Zachary J Thompson; Ernest K Amankwah; Nina Naas; Eric B Haura; Amer A Beg; Matthew B Schabath
Journal:  Mol Carcinog       Date:  2015-01-18       Impact factor: 4.784

2.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.

Authors:  Ramón Rami-Porta; Hisao Asamura; Peter Goldstraw
Journal:  Transl Lung Cancer Res       Date:  2015-08

3.  Prognostic value of metastatic N1 lymph node ratio and angiolymphatic invasion in patients with pathologic stage IIA non-small cell lung cancer.

Authors:  Ching-Feng Wu; Ching-Yang Wu; Jui-Ying Fu; Chi-Wei Wang; Yun-Hen Liu; Ming-Ju Hsieh; Yi-Cheng Wu
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

4.  A nomogram prognostic model for large cell lung cancer: analysis from the Surveillance, Epidemiology and End Results Database.

Authors:  Gang Lin; Kang Qi; Bing Liu; Haibo Liu; Jian Li
Journal:  Transl Lung Cancer Res       Date:  2021-02

5.  MicroRNA‑671‑5p inhibits cell proliferation, migration and invasion in non‑small cell lung cancer by targeting MFAP3L.

Authors:  Junhui Ye; Wujun Luo; Lingling Luo; Limin Zhai; Pingping Huang
Journal:  Mol Med Rep       Date:  2021-11-29       Impact factor: 2.952

6.  Prognostic factors in operated T3 non-small cell lung cancer: A retrospective, single-center study of 129 patients.

Authors:  Ahmet Uluşan; Maruf Şanlı; Ahmet Feridun Işık; Miray Ersöz; Bülent Tunçözgür; Kemal Bakır; Seval Kul; Levent Elbeyli
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-01-09       Impact factor: 0.332

Review 7.  Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer--A Structured Review with Meta-Analysis.

Authors:  Thomas K Kilvaer; Erna-Elise Paulsen; Sigurd M Hald; Tom Wilsgaard; Roy M Bremnes; Lill-Tove Busund; Tom Donnem
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

8.  Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis.

Authors:  Emilie Dalloneau; Nadine Baroukh; Konstantinos Mavridis; Agnès Maillet; Fabien Gueugnon; Yves Courty; Agnès Petit; Thomas Kryza; Maguy Del Rio; Serge Guyetant; Diana Carolina Cadena Castaneda; Christine Dhommée; Christophe Arnoult; Andreas Scorilas; Valérie Gouilleux-Gruart; Nathalie Heuzé-Vourc'h
Journal:  Oncotarget       Date:  2016-08-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.